Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

Summary

This phase III trial studies response-based chemotherapy in treating newly diagnosed acute myeloid leukemia or myelodysplastic syndrome in younger patients with Down syndrome. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Response-based chemotherapy separates patients into different risk groups and treats them according to how they respond to the first course of treatment (Induction I). Response-based treatment may be effective in treating acute myeloid leukemia or myelodysplastic syndrome in younger patients with Down syndrome while reducing the side effects.

Timeline

Start

2015-12-23

Primary completion

2024-06-30

Completion

2026-06-30

Publications

• Berman JN, Verma A, Viola S, Alonzo TA, Wang YC, Brodersen LE, Loken M, Beckman A, Hirsch B, Raimondi S, Chisholm KM, Ma X, Ries R, Meshinchi S, Gamis A, Schore R, Taub JW, Kolb EA, Cooper T, Hitzler J. Molecular risk markers define risk of relapse in myeloid leukemia of Down syndrome beyond measurable residual disease. Blood Adv. 2026 Mar 10;10(5):1576-1586. doi: 10.1182/bloodadvances.2025017837.

Drugs

Indications